Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy

Catherine B. Meyerle, K. Bailey Freund, Pawan Bhatnagar, Viral Shah, Lawrence A. Yannuzzi

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.

Original languageEnglish (US)
Pages (from-to)943-946
Number of pages4
Issue number7
StatePublished - Sep 1 2007


  • Central serous chorioretinopathy
  • Cortisol
  • Ketoconazole
  • Steroids

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this